Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Melphalan”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Study completedNCT00002678
What this trial is testing

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
NCIC Clinical Trials Group 595
Testing effectiveness (Phase 2)Study completedNCT00911859
What this trial is testing

Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 118
Large-scale testing (Phase 3)Study completedNCT01241708
What this trial is testing

Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma

Who this might be right for
Multiple MyelomaAuto Stem Cell Transplant
Hackensack Meridian Health 148
Testing effectiveness (Phase 2)Study completedNCT00477750
What this trial is testing

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 33
Early research (Phase 1)Study completedNCT00477815
What this trial is testing

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 30
Testing effectiveness (Phase 2)Study completedNCT01690143
What this trial is testing

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

Who this might be right for
Multiple Myeloma
University of Alabama at Birmingham 45
Testing effectiveness (Phase 2)WithdrawnNCT02406508
What this trial is testing

Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC

Who this might be right for
Hepatocellular Carcinoma (HCC)
Delcath Systems Inc.
Testing effectiveness (Phase 2)Active Not RecruitingNCT03192397
What this trial is testing

Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Who this might be right for
Acute Myeloid Leukemia in RemissionAdult Acute Lymphoblastic Leukemia in Complete RemissionChronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission+10 more
Roswell Park Cancer Institute
Testing effectiveness (Phase 2)Active Not RecruitingNCT03821610
What this trial is testing

A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)

Who this might be right for
Acute Lymphoblastic Leukemia
University of Birmingham 242
Not applicableLooking for participantsNCT06245629
What this trial is testing

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Who this might be right for
Myeloma Multiple
Uppsala University 100
Large-scale testing (Phase 3)Study completedNCT00002548
What this trial is testing

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Who this might be right for
Multiple Myeloma
SWOG Cancer Research Network 899
Large-scale testing (Phase 3)Ended earlyNCT00573391
What this trial is testing

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

Who this might be right for
Multiple Myeloma
University of Arkansas 5
Testing effectiveness (Phase 2)Looking for participantsNCT07025824
What this trial is testing

Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation

Who this might be right for
AML - Acute Myeloid LeukemiaMDS (Myelodysplastic Syndrome)
Technische Universität Dresden 220
Testing effectiveness (Phase 2)Ended earlyNCT00843310
What this trial is testing

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

Who this might be right for
Multiple Myeloma
NYU Langone Health 8
Testing effectiveness (Phase 2)Study completedNCT03583424
What this trial is testing

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Who this might be right for
Hematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+9 more
Ohio State University Comprehensive Cancer Center 19
Testing effectiveness (Phase 2)WithdrawnNCT03100877
What this trial is testing

Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma

Who this might be right for
Plasma Cell Leukemia in RemissionPlasma Cell Myeloma
City of Hope Medical Center
Testing effectiveness (Phase 2)Study completedNCT00003146
What this trial is testing

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Fred Hutchinson Cancer Center
Not applicableUnknownNCT05218603
What this trial is testing

Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

Who this might be right for
Multiple MyelomaNon-eligible for Autologous Stem Cell Transplantation (ASCT)
PETHEMA Foundation 100
Early research (Phase 1)Study completedNCT00968760
What this trial is testing

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Who this might be right for
LymphomaB-cell Lymphoma
M.D. Anderson Cancer Center 34
Testing effectiveness (Phase 2)Study completedNCT01039025
What this trial is testing

TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 60
Next Page
35